SCHEMBL24317769

SCHEMBL24317769

CCOC(=O)c1cc(Cc2ccc3c4c(cccc24)N(Cc2ccc(OC)cc2)C3=O)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CHRM5 P08912 2/20 0.40
LMNA P02545 3/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
THRB P10828 1/20 0.38
HPGD P15428 2/20 0.38
UBE2N P61088 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CHRM1 P11229 1/20 0.37
ACE P12821 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29532752 1.00 TDP1 (0.42) TDP1KDM4ECHRM5LMNAALDH1A1
SCHEMBL24317582 0.87 LMNA (0.45) KDM4ECHRM5LMNAALDH1A1MAPT
SCHEMBL24317614 0.81 TDP1 (0.46) TDP1KDM4ECHRM5LMNAALDH1A1
SCHEMBL24317764 0.81 KDM4E (0.51) TDP1KDM4ECHRM5LMNAMAPT
SCHEMBL24317734 0.79 TDP1 (0.48) TDP1KDM4ECHRM5LMNAALDH1A1
SCHEMBL24315886 0.78 KDM4E (0.57) TDP1KDM4ECHRM5LMNAALDH1A1
SCHEMBL24315767 0.76 KDM4E (0.57) TDP1KDM4ECHRM5LMNAMAPT
SCHEMBL22532551 0.76 KDM4E (0.57) TDP1KDM4ECHRM5LMNAMAPT
SCHEMBL22533762 0.75 KDM4E (0.52) TDP1KDM4ECHRM5LMNAALDH1A1
SCHEMBL27006357 0.75 KDM4E (0.49) TDP1KDM4ECHRM5LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 TDP1 383/4885KDM4E 791/4885CHRM5 4210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.